Nada Elbuluk, MD: New Research on Psychological Comorbidities in Patients with Vitiligo

Dr. Elbuluk discusses a recently published retrospective chart review that she and her colleagues published in the Archives of Dermatological Research,1 which included all patients diagnosed with vitiligo treated at a private hospital and a public hospital over a period of ten years, with a focus on associated psychiatric comorbidities. She summarizes the findings of rates of anxiety and depression in patients with vitiligo in terms of gender, race, and socioeconomic status.

Reference

  1. Montgomery SN, Snyder N, N Barajas G, Elbuluk N. Psychological comorbidities of vitiligo: a retrospective cross-sectional analysis in an urban population. Archives of Dermatological Research. 2024;316:14.

Disclosures: Expert Perspectives in Vitiligo is supported by InCyte. Dr. Elbuluk has served as a consultant and advisory board member for InCyte. However, the study discussed by Dr. Elbuluk in this series was not done in association with Incyte and received no funding from Incyte.

MORE EXPERT PERSPECTIVES IN VITILIGO

Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.

Dr. Seneschal discusses currently available topical JAKs for vitiligo, systemic JAKs being trialed to treat the condition in the future, and how JAKs can be

Jennifer Silva discusses a few treatment strategies to utilize in patients who continue to struggle to find effective treatment for their vitiligo.

Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical

Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.

Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment

Gina Mangin discusses the importance of educating patients on the expected timeline for repigmentation when utilizing light box therapy.

Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1

Shanna Miranti speaks to the importance of trying and failing with topical corticosteroids and topical calcineurin inhibitors prior to prescribing patients with topical ruxolitinib.

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster
Shanna Miranti, MPAS, PA-C, discusses the similar efficacy seen in patients treated with ruxolitinib at diagnosis versus those who had disease for years.
Shanna Miranti, MPAS, PA-C, discusses the bimodal distribution of vitiligo in male and female individuals and the necessary counseling for those who are managing their
Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially
Andrea Nguyen discusses how she counsels patients with vitiligo and emphasizes the importance in communicating with patients about consistent application and dosing during a treatment
Dr. Chovatiya discusses how to effectively treat patients with nonsegmental vitiligo using topical ruxolitinib cream and the importance in a slow and steady treatment regimen.
Dr. Elbuluk discusses results of the clinical trials for ruxolitinib cream in patients with vitiligo and how this treatment is being incorporated into the dermatologist’s
John Harris, MD, PhD, Chair of Dermatology at UMass Chan Medical School, discusses the impact topical ruxolitinib cream has had on patients with vitiligo. He
Susan Taylor, MD, Professor of Dermatology at The University of Pennsylvania in Philadelphia, Pennsylvania, reviews the burden of vitiligo on patients of color and reviews
Nada Elbuluk, MD, a board certified dermatologist at the University of Southern California in Los Angeles, California, discusses the importance of offering a variety of
John Harris, MD, PhD, Chair of Dermatology at Umass Chan Medical School, reviews the history of treatments for vitiligo, current treatments for vitiligo and their
Pearl Grimes, MD, Director of of Vitiligo and Pigmentation Institute of Southern California and Clinical Professor of Dermatology at UCLA discusses exciting advancements in therapy